About us

At TJ Bio, we are committed to bringing life-changing therapies from lab to patients, transforming care for autoimmune diseases, immuno-oncology, and metabolic disorders worldwide. As a fully integrated biotech company, we have established a seamless value chain spanning discovery, clinical development, manufacturing, and commercial partnerships.

Anchored by R&D hubs in Shanghai and Beijing and a state-of-the-art GMP manufacturing center in Hangzhou, this robust infrastructure powers our differentiated "Two-Wave" pipeline. This strategy balances fast-to-market products approaching commercialization with a next generation of First-in-Class assets derived from our proprietary AntibodyPLUS platform. Driven by a diversified sustainable revenue model – comprising product out-licensing, CDMO services, and commercialization royalties – we are accelerating our evolution from an R&D pioneer to a global biopharmaceutical leader.

Platform-Powered Innovation

Beijing

Hangzhou Manufacturing Facility (Headquarters)

· Drug Manufacturing Permit Holder

· GMP manufacturing + CMC & formulation labs

· Clinical & commercial production: 3x2kL expandable to 6x2kL

Shanghai R&D Center

· Research laboratory

· Clinical development

· Corporate functions

Beijing Center

· Clinical development

· Regulatory affairs

· Government affairs

Our Pipeline

Advanced and Differentiated Pipeline

Metabolic Diseases
Immuno-Oncology
Inflammatory Diseases
AssetsAreasIndicationsPre-ClinicalPhase 1Phase 2Phase 3BLAPartnershipRights *
1
Near-Term Product Pipeline
Aiming for product launches in 2026 and multiple BLA submissions in 2027
Fast-to-market
Best-in-Class Potential
Felzartamab CD38
Multiple Myeloma
IgA Nephropathy
PMN
BLA submitted Dec 2024
PREVAIL
PROMINENT
BTD and ODD granted (FDA)
Greater China
Eftansomatropin alfa Long-acting hGH
PGHD
BLA submitted Dec 2024
China
Efmedaglutide alfa Long-acting GLP-1
Obesity
Diabetes
BLA submitted Oct 2025
China
Plonmarlimab GM-CSF
MAS/sHLH
Gouty Arthritis
MALS
PRIME-1
BTD granted (NMPA)
PRIME-2
PRIME-3
Global
Uliledlimab CD73
NSCLC (1L Doublet)
NSCLC (1L Triplet)
UPLIFT
SPARK
Greater China
Givastomig Claudin18.2 x 4-1BB
Gastric cancer
ODD granted (FDA)
Greater China
2
Next-Generation Pipeline
Platform-enabled IND-ready and Phase 1 assets
Powered by Antibody PLUS
First-in-Class Potential
TJ-C64B BsAb
Ovarian Cancer, Endometrial Cancer, AFP+ Gastric Cancer
IND approved, Phase 1 ready
Global
TJ-L1IF Immunocytokine
PD-1-resistant Cancers
Global
TJ-MC203 TsAb
Severe Autoimmune Diseases e.g. SLE, Systemic Sclerosis
Global
TJ-TL23 BsAb
Inflammatory Bowel Disease
Global
TJ-RO4B TsAb
Pan Solid-tumors
Global
TJ-AGC AGC
Autoimmune Diseases
Global
Other clinical assets including:
efineptakin alfa (a phase 2 stage, long-acting IL-7 fusion protein for treatment in multiple cancers),
izastobart (a phase 1/2 stage, C5aR1 antibody for treatment in multiple autoimmune diseases), and
TJ-L1A3 (a phase 1 stage, PD-L1 x LAG3 BsAb for treatment in multiple cancers).
Abbreviations: PMN = Primary Membranous Nephropathy; PGHD = Pediatric Growth Hormone Deficiency; MAS = Macrophage Activation Syndrome; sHLH = Secondary Hemophagocytic Lymphohistiocytosis; MALS = Macrophage Activation Like Sepsis; NSCLC = Non-Small Cell Lung Cancer; BsAb = Bi-specific Antibody; TsAb = Tri-specific Antibody; 1L = First-Line Treatment; Doublet = Uliledlimab + PD-1; Triplet = Uliledlimab + PD-1 + Chemotherapy; BTD = Breakthrough Therapy Designation; ODD = Orphan Drug Designation; BLA = Biologic License Application; IND = Investigational New Drug; NMPA = China National Medical Products Administration; FDA = US Food and Drug Administration
* “Rights” refers to TJ Biopharma’s interests associated with each asset in the specified territories, which may include rights for development, manufacturing, commercialization, and/or eligibility for milestone payments and royalties.

News Center

Learn more
Learn more